# Revisto

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revisto

- Industry: Software
- Headquarters: San Antonio, US
- Website: www.revisto.com
- Total disclosed funding: $4M
- Latest round: Seed (Nov 18, 2024)
- Investors on record: 4

## About

Founded in 2023, and based in Texas, US, Revisto, Inc. engaged in AI solutions for marketing compliance in life sciences. The firm raised USD 4.000 mn in Seed funding on November 18, 2024, led by LiveOak Venture Partners and supported by Eli Lilly & Company, Tau Ventures, and Arkin Holdings. Ferry Tamtoro  (CEO) and Jaya Plmanabhan co-founded the firm.

Revisto offers an AI-driven platform designed to facilitate the creation and compliance review of marketing materials specifically for the life sciences sector. Their core product offerings include automated tools that enable marketing teams to generate credible sources for claims made in promotional materials, substantially reducing the time spent on manual research and compliance checks. The platform enhances the review process by flagging potential compliance issues early, allowing teams to focus on creating content while maintaining adherence to industry standards and regulations. Revisto serves a diverse client base, including pharmaceutical companies and biotech firms, predominantly in the North American and European markets. 

Revisto's revenue structure is primarily based on subscription models, where clients pay for access to the platform's suite of compliance and content creation tools.

In November 2024, Revisto, Inc. raised USD 4.000 mn in Seed funding, which will be utilized to expand their team and accelerate product development, particularly enhancing the engine's detection and recommendation capabilities. The company aims to launch new products focused on improving compliance automation tools by mid-2025. Revisto is also targeting expansion into the European market, with plans to establish a presence in key countries such as Germany and France by the end of 2025.

## Funding rounds

- Seed, Nov 18, 2024, $4M — Eli Lilly & Company, LiveOak Venture, Arkin Capital, Tau Ventures

## Investors

- Eli Lilly & Company — Seed
- LiveOak Venture (https://capitalatlas.ai/funds/liveoak-venture) — Seed
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Seed
- Tau Ventures — Seed